Nowak AK and Forde P. Immunotherapy trials in mesothelioma – promising results, but don’t stop here. Nature Reviews ClinicaOncology. 2019 Dec;16(12):726-728. doi: 10.1038/s41571-019-0291-4.

 

Nicholson AG, Sauter JL, Nowak A, Kindler H, Gill R, Remy-Jardin M, Armato S, Fernandez-Cuesta L, Bueno R, Alcala N, Foll M, Pass H, Attanoos R, Baas P, Beasley MB, Brcic L, Butnor KJ, Chiriac LR, Churg A, Courtiolt P, Dacic S, De Perrot M, Frauenfelder T, Gibbs A, Hirsch FR, Hiroshima K, Husain A, Klebe S, Lantejoul S, Moreira A, Opitz I, Perol M, ROden A, ROggli V, Scherpereel A, Tirode F, Tazelaar H, Travis WD, Tsao MS, van Schil P, Vignaud JM, Weynand R, Cree I, Rusch VW, Girard N, Galateau-Salle F. EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach.  Journal of Thoracic Oncology 2019 Sep 20. pii: S1556-0864(19)33232-0. doi: 10.1016/j.jtho.2019.08.2506. [Epub ahead of print]

 

Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG, Francis RJ, Gomez DR, Dahlberg S, Rimner A, Simone CB, de  Perrot M, Blumenthal G, Adjei AA, Bueno R, Harpole DH, Hesdorffer M, Hirsch FR, Pass HI, Yorke E, Rosenzweig K, Burt B, Fennell DA, Lindwasser W, Malik S, Peikert T, Mansfield AS, Salgia R, Yang, J, Rusch, VW, Nowak AK. Radiologic Considerations And Standardization Of Malignant Pleural Mesothelioma (MPM) Imaging Within Clinical Trials: Consensus Guidelines From The NCI Thoracic Malignancy Steering Committee – International Association For The Study Of Lung Cancer – Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. Journal of Thoracic Oncology 2019 Oct;14(10):1718-1731. doi: 10.1016/j.jtho.2019.08.012. Epub 2019 Aug 27

Aston WJ, Hope DE, Cook AM, Boon L, Dick INowak AKLake RA, Lesterhuis WJ. Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment. Oncoimmunol, 2019 Jul 13;8(11):e1641390. doi: 10.1080/2162402X.2019.1641390. eCollection 2019.

Zemek RM, De Jong E, Chin WL, Schuster IA, Fear VS, Casey TS, Forbes C, Dart SJ, Leslie C, Zaitouny A, Small M, Boon L, Forrest ARR, Muiri DO, Degli-Espositi MA, Millward MJ, Nowak AK, Lassman T, Bosco A, Lake RALesterhuis WJ. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. Science Translational Medicine. 2019 Jul 17;11(501):eaav7816. doi:10.1126/scitranslmed.aav7816.

Tsao M-S, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AJ, Adjei AA, Aubry M-C, Fennell DA, Gomez D, Harpole D, Hesdorffer M, Hirsch FR, Liu F, Malik S, Nowak A, Peikert T, Salgia R, Szlosarek P, Taioli E, Yang H, Tsao A, Mansfield AS. Pathologic considerations and standardization in mesothelioma clinical trials. Journal of Thoracic Oncology, 2019 Oct;14(10):1704-1717. doi: 10.1016/j.jtho.2019.06.020.

Scagliotti G, Gaafar R; Nowak AK; Nakano T; van Meerbeeck J; Popat S; Vogelzang NJ; Grosso F; Aboelhassan R; Jakopovic M; Ceresoli GL; Taylor P; Orlandi F; Fennell DA; Novello S; Scherpereel A; Kuribayashi K; Cedres S; Sørensen JB; Pavlakis N; Reck M; Velema D; von Wangenheim U; Kim M; Barrueco J; Tsao AS. LUME-Meso: double-blind, placebo-controlled phase 3 trial of nintedanib in combination with pemetrexed/cisplatin for chemotherapy-naïve patients with advanced malignant pleural mesothelioma. Lancet Resp Med 2019; 7(7): 569-580. PMID: 31103412 https://dx.doi.org/10.1016/S2213-2600(19)30139-0

Tsao A, Nakano T, Nowak AK, Popat S, Scagliotti GV, Heymach J. Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma. Manuscript accepted, Seminars in Oncology, Epub ahead of print 18/07/19.  PMID: 31280996 DOI: https://doi.org/10.1053/j.seminoncol.2019.06.001

Jeffery E, Lee YCG, Newton RU, Lyons-Wall P, McVeigh J, Nowak AK, Cheah HM, Nguyen B, Fitzgerald DB, Creaney J, Straker L, Peddle-McIntyre CJ. Body composition and nutritional status in malignant pleural mesothelioma: implications for activity levels and quality of life. Eur J Clin Nutr. 2019 Oct;73(10):1412-1421. doi: 10.1038/s41430-019-0418-9. PMID: 30886321

Fear VS, Forbes CA, Chee J, Ma S, Neeve S, Celliers L, Fisher SA, Dick I, Creaney J, Robinson BWS. Neo-antigen specific T cell responses indicate the presence of metastases before imaging. Sci Rep. 2019 Oct 10;9(1):14640

Trivedi PM, Fynch S, Kennedy LM, Chee J, Krishnamurthy B, O’Reilly LA, Strasser A, Kay TWH, Thomas HE. Soluble FAS ligand is not required for pancreatic islet inflammation or beta-cell destruction in non-obese diabetic mice. Cell Death Discov. 2019 Sep 23;5:136

Chee J, Wilson C, Buzzai A, Wylie B, Forbes CA, Booth M, Principe N, Foley B, Cruickshank MN, Waithman J. Impaired T cell proliferation by ex vivo BET-inhibition impedes adoptive immunotherapy in a murine melanoma model. Epigenetics. 2019 Aug 26:1-11

Wylie B*, Chee J*, Forbes CA, Booth M, Stone SR, Buzzai A, Abad A, Foley B, Cruickshank MN, Waithman J. Acquired resistance during adoptive cell therapy by transcriptional silencing of immunogenic antigens. Oncoimmunology. 2019 Jun 3;8(8):1609874

Ma S, Chee J, Fear VS, Forbes CA, Boon L, Dick IBWS RobinsonCreaney J. Pre-treatment tumour neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome. Oncolimmunology. 2019 Nov 7;9(1):1684714.

doi: 10.1080/2162402X.2019.1684714. eCollection 2020.

2018

Mollah ZUA, Quah HS, Graham KL, Jhala G, Krishnamurthy B, Dharma JFM, Chee J, Trivedi PM, Pappas EG, Mackin L, Chu EPF, Akazawa S, Fynch S, Hodson C, Deans AJ, Trapani JA, Chong MMW, Bird PI, Brodnicki TC, Thomas HE, Kay TWH. Granzyme A Deficiency Breaks Immune Tolerance and Promotes Autoimmune Diabetes Through a Type I Interferon-Dependent Pathway. Diabetes. 2017 Dec;66(12):3041-3050

Tsao AS,  Lindwasser OW; Adjei, AA; Adusumilli, PS); Beyers, ML; Blumenthal, GM; Bueno, R; Burt, BM; Carbone, M; Dahlberg, SE; de Perrot, M; Fennell , DA; Friedberg, J; Gill, RR; Gomez, DR; Harpole, DH  Hassan, R; Hesdorffer, M; Hirsch, FR; Hmeljak, J; Kindler, HL; Korn, EL; Liu, G; Mansfield, AS; Nowak, AK ; Pass, HI; Peikert, T; Rimner, A; Robinson, BWS; Rosenzweig, KE; Rusch, VW; Salgia, R; Sepesi, B; Simone, CB; Sridhara, R; Szlosarek, P ; Taioli, E; Tsao, MS; Yang, HN ; Zauderer, MG, Malik SM. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2018. 13(11); 1655-1667.

Fear VS, Tilsed C, Chee J, Forbes CA, Casey R, Solin JN, Lansley SM, Lesterhuis WJDick IMNowak AKRobinson BWSLake RAFisher SF. Combination immune checkpoint blockade as an effective therapy for mesothelioma. Oncoimmunology. 2018 Jul 30;7(10):e1494111. doi: 10.1080/2162402X.2018.1494111. eCollection 2018. PMID: 30288361

Harris EJA, Kao S, Nakano T, Kondo N, Hyland R, Nowak AK, de Klerk N, Brims FJH. Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery. J Thorac Oncol. 2019 Feb;14(2):288-293. doi: 10.1016/j.jtho.2018.10.005. PMID 30366103

Chee J, Watson MW, Chopra A, Nguyen B, Cook AMCreaney JLesterhuis WJRobinson BW, Lee YCG, Nowak AKLake RA, McDonnell AM. Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors. BMC Res Notes. 2018 Dec 5;11(1):864. doi: 10.1186/s13104-018-3953-x.

Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, Pachter JA, Weaver DT, Scherpereel A, Pavlakis N, van Meerbeeck JP, Cedres S, Nolan L, Kindler H, Aerts JGJV. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. J Clin Oncol. 2019 Apr 1;37(10):790-798. doi: 10.1200/JCO.2018.79.0543. PMID: 30785827

Metaxas Y, Rivalland G, Klingbiel D, Kao S, Schmid S, Nowak AK, Gautschi O, Bartnick T, Hughes B, Bouchaab H, Rothschild S, Pavlakis N, Wolleb S, Petrausch U, O’Byrne K, Frösch P, Baumann-Löffler M,  Pratsch-Peter S, Russell P, Mingrone W, Savic-Prince, Thapa B, Pless M, von Moos R, Mauti L, John T.  Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma: a real-world analysis. J Thorac Oncol 2018: 13(11): 1784-91. https://doi.org/10.1016/j.jtho.2018.08.007

Armato S, Nowak AK. Revised Modified RECIST Criteria for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1). J Thorac Oncol 2018; 13(7): 1012-1021

2017

Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, John R, Leighl NB, Reck M, Taylor P, Planchard D, Sorensen JB, Socinski MA, von Wangenheim U, Loembe A-B, Barrueco J, Morsli N, Scagliotti G. Nintedanib plus Pemetrexed/Cisplatin in Patients with Malignant Pleural Mesothelioma: Phase II Results from the Placebo-Controlled LUME-Meso Trial. J Clin Oncol 2017: 35(31): 3591-3600 DOI: 10.1200/JCO.2017.72.9012

Aston WJ, Hope DE, Nowak AKRobinson BWSLake RALesterhuis WJ. A  Systematic Investigation of the Maximum Tolerated Dose of Cytotoxic Chemotherapy with and without Supportive Care in Mice.  BMC Cancer 2017 17: 684. DOI: 10.1186/s12885-017-3677-7

Maio M, Scherpereel A, Calabro L, Aerts J, Cedres Perez S, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman P, Kindler HL. Tremelimumab as second- and third-line treatment in relapsed malignant mesothelioma (MM): a phase 2b, randomised, double blind, placebo-controlled study (DETERMINE). Lancet Oncol 2017; 18(9): 1261-73

Scagliotti G, Gaafar R, Nowak AK, Reck M, Tsao AS, van Meerbeeck J, Vogelzang N, Nakano T, von Wangenheim U, Velema D, Morsli N, Popat S. LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients with Unresectable Malignant Pleural Mesothelioma. Manuscript published online, Clin Lung Cancer 18(5): 589-93. doi.org/10.1016/j.cllc.2017.03.010

McDonnell AM, Cook AMRobinson BWSLake RANowak AK. Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters. BMC Cancer (2017) 17:417 DOI 10.1186/s12885-017-3403-5

Lesterhuis WJ, Bosco A, Millward MJ, Small M, Nowak AKLake RA. Dynamic versus static biomarkers in cancer immune checkpoint blockade – unraveling complexity. Nat Rev Drug Discovery. 2017; 16(4): 264-272. Http://dx.doi.org.10.1038.nrd.2016.233

Nowak AKCook AM, McDonnell A. Immune checkpoint inhibition for the treatment of mesothelioma. Expert Opinion on Biological Therapy. 2019; 19(7): 697-706.

McCambridge AJ, Napolitano A, Mansfield AS, Fennell D, Sekido Y, Nowak AK, Pass HI, Carbone M, Yang H, Peikert T. Progress in the Management of Malignant Pleural Mesothelioma in 2017. J Thorac Oncol 2018; 13(5): 606-623.

Nowak AK, Armato SG. Measuring Malignant Pleural Mesothelioma. Chapter In: Mesothelioma:  From Research to Clinical Practice. Ed:   Giovanni  Luca Ceresoli, Emilio Bombardieri, Maurizio D’Incalci. Springer NY 2018

Baas P, Hassan R, Nowak AK, Rice D. Chapter 53: Malignant Mesothelioma. In: The IASLC Multidisciplinary Approach to Thoracic Oncology. Elsevier. 2017

Nowak AK, Edwards JG, Creaney J. Chapter 16: Mesothelioma. Textbook of Uncommon Cancers, 5th Edition. P 266-284. Ed. D Rhagavan, M Ahluwallia, C Blanke, J Brown, E Kim, G Reaman, and M Sekeres. Wiley-Blackwell. Chichester, UK. 2017 ISBN: 978-1-119-19620-4

Chee J, Holt RA, Robinson BCreaney J. Immunotherapy of lung malignancies – from gene sequencing to novel therapies. Chest. 2017 Apr;151(4):891-897

Fisher SA, Aston WJ, Chee J, Khong A, Cleaver AL, Solin JN, et al. Transient Treg depletion enhances therapeutic anti-cancer vaccination. Immun Inflamm Dis. 2017;5(1):16-28

Menu